APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Radioligands Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Therapeutic Radioligands Drug Market Outlook and Growth Opportunities 2026

29 December 2025200 pages

Choose your research edition.

Industry ResearchTherapeutic Radioligands Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Radioligands Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Therapeutic Radioligands Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Radioligands Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Radioligands Drug Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Therapeutic Radioligands Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Therapeutic Radioligands Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Therapeutic Radioligands Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Radioligands Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Therapeutic Radioligands Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Therapeutic Radioligands Drug market include Novartis, Mundipharma, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med and Nordic Nanovector, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Therapeutic Radioligands Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Radioligands Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Radioligands Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Therapeutic Radioligands Drug market.

Therapeutic Radioligands Drug Segment by Company

Novartis

Mundipharma

Bayer

Y-mAbs Therapeutics

Telix Pharmaceuticals

RadioMedix

Philogen

Orano Med

Nordic Nanovector

Lantheus

Gilead Sciences

Fusion Pharmaceuticals

Curium Pharmaceuticals

Curasight

Clarity Pharmaceuticals

China Isotope & Radiation

Aurobindo Pharma

Actinium Pharmaceuticals

Therapeutic Radioligands Drug Segment by Type

Beta-emitting

Targeted Alpha Therapy

Therapeutic Radioligands Drug Segment by Application

Solid Tumor

Non Hodgkin Lymphoma

Therapeutic Radioligands Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Therapeutic Radioligands Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Therapeutic Radioligands Drug key companies, revenue, market share, and recent developments.

3. To split the Therapeutic Radioligands Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Therapeutic Radioligands Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Therapeutic Radioligands Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Therapeutic Radioligands Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Radioligands Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Radioligands Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Radioligands Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Radioligands Drug industry.

Chapter 3: Detailed analysis of Therapeutic Radioligands Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Therapeutic Radioligands Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Therapeutic Radioligands Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Therapeutic Radioligands Drug Industry Trends Table 2. Therapeutic Radioligands Drug Industry Drivers Table 3. Therapeutic Radioligands Drug Industry Opportunities and Challenges Table 4. Therapeutic Radioligands Drug Industry Restraints Table 5. Global Therapeutic Radioligands Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Therapeutic Radioligands Drug Revenue Share by Company (2021-2026) Table 7. Global Therapeutic Radioligands Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Therapeutic Radioligands Drug Key Company Manufacturing Base & Headquarters Table 9. Global Therapeutic Radioligands Drug Company, Product Type & Application Table 10. Global Therapeutic Radioligands Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Therapeutic Radioligands Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Beta-emitting Table 15. Significant Companies of Targeted Alpha Therapy Table 16. Global Therapeutic Radioligands Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Therapeutic Radioligands Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Therapeutic Radioligands Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Therapeutic Radioligands Drug Sales Value Share by Type (2021-2026) Table 20. Global Therapeutic Radioligands Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Solid Tumor Table 22. Significant Companies of Non Hodgkin Lymphoma Table 23. Global Therapeutic Radioligands Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Therapeutic Radioligands Drug Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Therapeutic Radioligands Drug Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Therapeutic Radioligands Drug Sales Value Share by Application (2021-2026) Table 27. Global Therapeutic Radioligands Drug Sales Value Share by Application (2027-2032) Table 28. Global Therapeutic Radioligands Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Therapeutic Radioligands Drug Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Therapeutic Radioligands Drug Sales Value Share by Region (2021-2026) Table 31. Global Therapeutic Radioligands Drug Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Therapeutic Radioligands Drug Sales Value Share by Region (2027-2032) Table 33. Global Therapeutic Radioligands Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Therapeutic Radioligands Drug Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Therapeutic Radioligands Drug Sales Value Market Share by Country (2021-2026) Table 36. Global Therapeutic Radioligands Drug Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Therapeutic Radioligands Drug Sales Value Market Share by Country (2027-2032) Table 38. Novartis Company Information Table 39. Novartis Business Overview Table 40. Novartis Therapeutic Radioligands Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Novartis Therapeutic Radioligands Drug Product Portfolio Table 42. Novartis Recent Development Table 43. Mundipharma Company Information Table 44. Mundipharma Business Overview Table 45. Mundipharma Therapeutic Radioligands Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Mundipharma Therapeutic Radioligands Drug Product Portfolio Table 47. Mundipharma Recent Development Table 48. Bayer Company Information Table 49. Bayer Business Overview Table 50. Bayer Therapeutic Radioligands Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Bayer Therapeutic Radioligands Drug Product Portfolio Table 52. Bayer Recent Development Table 53. Y-mAbs Therapeutics Company Information Table 54. Y-mAbs Therapeutics Business Overview Table 55. Y-mAbs Therapeutics Therapeutic Radioligands Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Portfolio Table 57. Y-mAbs Therapeutics Recent Development Table 58. Telix Pharmaceuticals Company Information Table 59. Telix Pharmaceuticals Business Overview Table 60. Telix Pharmaceuticals Therapeutic Radioligands Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Telix Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio Table 62. Telix Pharmaceuticals Recent Development Table 63. RadioMedix Company Information Table 64. RadioMedix Business Overview Table 65. RadioMedix Therapeutic Radioligands Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. RadioMedix Therapeutic Radioligands Drug Product Portfolio Table 67. RadioMedix Recent Development Table 68. Philogen Company Information Table 69. Philogen Business Overview Table 70. Philogen Therapeutic Radioligands Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Philogen Therapeutic Radioligands Drug Product Portfolio Table 72. Philogen Recent Development Table 73. Orano Med Company Information Table 74. Orano Med Business Overview Table 75. Orano Med Therapeutic Radioligands Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Orano Med Therapeutic Radioligands Drug Product Portfolio Table 77. Orano Med Recent Development Table 78. Nordic Nanovector Company Information Table 79. Nordic Nanovector Business Overview Table 80. Nordic Nanovector Therapeutic Radioligands Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Nordic Nanovector Therapeutic Radioligands Drug Product Portfolio Table 82. Nordic Nanovector Recent Development Table 83. Lantheus Company Information Table 84. Lantheus Business Overview Table 85. Lantheus Therapeutic Radioligands Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Lantheus Therapeutic Radioligands Drug Product Portfolio Table 87. Lantheus Recent Development Table 88. Gilead Sciences Company Information Table 89. Gilead Sciences Business Overview Table 90. Gilead Sciences Therapeutic Radioligands Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Gilead Sciences Therapeutic Radioligands Drug Product Portfolio Table 92. Gilead Sciences Recent Development Table 93. Fusion Pharmaceuticals Company Information Table 94. Fusion Pharmaceuticals Business Overview Table 95. Fusion Pharmaceuticals Therapeutic Radioligands Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio Table 97. Fusion Pharmaceuticals Recent Development Table 98. Curium Pharmaceuticals Company Information Table 99. Curium Pharmaceuticals Business Overview Table 100. Curium Pharmaceuticals Therapeutic Radioligands Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Curium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio Table 102. Curium Pharmaceuticals Recent Development Table 103. Curasight Company Information Table 104. Curasight Business Overview Table 105. Curasight Therapeutic Radioligands Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Curasight Therapeutic Radioligands Drug Product Portfolio Table 107. Curasight Recent Development Table 108. Clarity Pharmaceuticals Company Information Table 109. Clarity Pharmaceuticals Business Overview Table 110. Clarity Pharmaceuticals Therapeutic Radioligands Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio Table 112. Clarity Pharmaceuticals Recent Development Table 113. China Isotope & Radiation Company Information Table 114. China Isotope & Radiation Business Overview Table 115. China Isotope & Radiation Therapeutic Radioligands Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. China Isotope & Radiation Therapeutic Radioligands Drug Product Portfolio Table 117. China Isotope & Radiation Recent Development Table 118. Aurobindo Pharma Company Information Table 119. Aurobindo Pharma Business Overview Table 120. Aurobindo Pharma Therapeutic Radioligands Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Aurobindo Pharma Therapeutic Radioligands Drug Product Portfolio Table 122. Aurobindo Pharma Recent Development Table 123. Actinium Pharmaceuticals Company Information Table 124. Actinium Pharmaceuticals Business Overview Table 125. Actinium Pharmaceuticals Therapeutic Radioligands Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio Table 127. Actinium Pharmaceuticals Recent Development Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Therapeutic Radioligands Drug Product Image Figure 2. Global Therapeutic Radioligands Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Radioligands Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Beta-emitting Image Figure 8. Targeted Alpha Therapy Image Figure 9. Global Therapeutic Radioligands Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Therapeutic Radioligands Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Therapeutic Radioligands Drug Sales Value Share by Type (2021-2032) Figure 12. Solid Tumor Image Figure 13. Non Hodgkin Lymphoma Image Figure 14. Global Therapeutic Radioligands Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Therapeutic Radioligands Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Therapeutic Radioligands Drug Sales Value Share by Application (2021-2032) Figure 17. Global Therapeutic Radioligands Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Therapeutic Radioligands Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Therapeutic Radioligands Drug Sales Value (2021-2032) & (US$ Million) Figure 20. North America Therapeutic Radioligands Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Therapeutic Radioligands Drug Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Therapeutic Radioligands Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Therapeutic Radioligands Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Therapeutic Radioligands Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Therapeutic Radioligands Drug Sales Value (2021-2032) & (US$ Million) Figure 26. South America Therapeutic Radioligands Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Therapeutic Radioligands Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Therapeutic Radioligands Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Beta-emitting
  • Targeted Alpha Therapy
Applications
  • Solid Tumor
  • Non Hodgkin Lymphoma
Companies covered
  • Novartis
  • Mundipharma
  • Bayer
  • Y-mAbs Therapeutics
  • Telix Pharmaceuticals
  • RadioMedix
  • Philogen
  • Orano Med
  • Nordic Nanovector
  • Lantheus
  • Gilead Sciences
  • Fusion Pharmaceuticals
  • Curium Pharmaceuticals
  • Curasight
  • Clarity Pharmaceuticals
  • China Isotope & Radiation
  • Aurobindo Pharma
  • Actinium Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Therapeutic Radioligands Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Therapeutic Radioligands Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Therapeutic Radioligands Drug Market Dynamics
  1. 2.1 Therapeutic Radioligands Drug Industry Trends
  2. 2.2 Therapeutic Radioligands Drug Industry Drivers
  3. 2.3 Therapeutic Radioligands Drug Industry Opportunities and Challenges
  4. 2.4 Therapeutic Radioligands Drug Industry Restraints
3 Therapeutic Radioligands Drug Market by Company
  1. 3.1 Global Therapeutic Radioligands Drug Company Revenue Ranking in 2025
  2. 3.2 Global Therapeutic Radioligands Drug Revenue by Company (2021-2026)
  3. 3.3 Global Therapeutic Radioligands Drug Company Ranking (2024-2026)
  4. 3.4 Global Therapeutic Radioligands Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Therapeutic Radioligands Drug Company Product Type and Application
  6. 3.6 Global Therapeutic Radioligands Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Therapeutic Radioligands Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Therapeutic Radioligands Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Therapeutic Radioligands Drug Market by Type
  1. 4.1 Therapeutic Radioligands Drug Type Introduction
  2. 4.1.1 Beta-emitting
  3. 4.1.2 Targeted Alpha Therapy
  4. 4.2 Global Therapeutic Radioligands Drug Sales Value by Type
  5. 4.2.1 Global Therapeutic Radioligands Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Therapeutic Radioligands Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Therapeutic Radioligands Drug Sales Value Share by Type (2021-2032)
5 Therapeutic Radioligands Drug Market by Application
  1. 5.1 Therapeutic Radioligands Drug Application Introduction
  2. 5.1.1 Solid Tumor
  3. 5.1.2 Non Hodgkin Lymphoma
  4. 5.2 Global Therapeutic Radioligands Drug Sales Value by Application
  5. 5.2.1 Global Therapeutic Radioligands Drug Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Therapeutic Radioligands Drug Sales Value by Application (2021-2032)
  7. 5.2.3 Global Therapeutic Radioligands Drug Sales Value Share by Application (2021-2032)
6 Therapeutic Radioligands Drug Regional Value Analysis
  1. 6.1 Global Therapeutic Radioligands Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Therapeutic Radioligands Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Therapeutic Radioligands Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Therapeutic Radioligands Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Therapeutic Radioligands Drug Sales Value (2021-2032)
  7. 6.3.2 North America Therapeutic Radioligands Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Therapeutic Radioligands Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Therapeutic Radioligands Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Therapeutic Radioligands Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Therapeutic Radioligands Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Therapeutic Radioligands Drug Sales Value (2021-2032)
  16. 6.6.2 South America Therapeutic Radioligands Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Therapeutic Radioligands Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Therapeutic Radioligands Drug Sales Value Share by Country, 2025 VS 2032
7 Therapeutic Radioligands Drug Country-level Value Analysis
  1. 7.1 Global Therapeutic Radioligands Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Therapeutic Radioligands Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Therapeutic Radioligands Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Therapeutic Radioligands Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Therapeutic Radioligands Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Therapeutic Radioligands Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Therapeutic Radioligands Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Therapeutic Radioligands Drug Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Mundipharma
  8. 8.2.1 Mundipharma Company Information
  9. 8.2.2 Mundipharma Business Overview
  10. 8.2.3 Mundipharma Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Mundipharma Therapeutic Radioligands Drug Product Portfolio
  12. 8.2.5 Mundipharma Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Therapeutic Radioligands Drug Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Y-mAbs Therapeutics
  20. 8.4.1 Y-mAbs Therapeutics Company Information
  21. 8.4.2 Y-mAbs Therapeutics Business Overview
  22. 8.4.3 Y-mAbs Therapeutics Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Portfolio
  24. 8.4.5 Y-mAbs Therapeutics Recent Developments
  25. 8.5 Telix Pharmaceuticals
  26. 8.5.1 Telix Pharmaceuticals Company Information
  27. 8.5.2 Telix Pharmaceuticals Business Overview
  28. 8.5.3 Telix Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Telix Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
  30. 8.5.5 Telix Pharmaceuticals Recent Developments
  31. 8.6 RadioMedix
  32. 8.6.1 RadioMedix Company Information
  33. 8.6.2 RadioMedix Business Overview
  34. 8.6.3 RadioMedix Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 RadioMedix Therapeutic Radioligands Drug Product Portfolio
  36. 8.6.5 RadioMedix Recent Developments
  37. 8.7 Philogen
  38. 8.7.1 Philogen Company Information
  39. 8.7.2 Philogen Business Overview
  40. 8.7.3 Philogen Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Philogen Therapeutic Radioligands Drug Product Portfolio
  42. 8.7.5 Philogen Recent Developments
  43. 8.8 Orano Med
  44. 8.8.1 Orano Med Company Information
  45. 8.8.2 Orano Med Business Overview
  46. 8.8.3 Orano Med Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Orano Med Therapeutic Radioligands Drug Product Portfolio
  48. 8.8.5 Orano Med Recent Developments
  49. 8.9 Nordic Nanovector
  50. 8.9.1 Nordic Nanovector Company Information
  51. 8.9.2 Nordic Nanovector Business Overview
  52. 8.9.3 Nordic Nanovector Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nordic Nanovector Therapeutic Radioligands Drug Product Portfolio
  54. 8.9.5 Nordic Nanovector Recent Developments
  55. 8.10 Lantheus
  56. 8.10.1 Lantheus Company Information
  57. 8.10.2 Lantheus Business Overview
  58. 8.10.3 Lantheus Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lantheus Therapeutic Radioligands Drug Product Portfolio
  60. 8.10.5 Lantheus Recent Developments
  61. 8.11 Gilead Sciences
  62. 8.11.1 Gilead Sciences Company Information
  63. 8.11.2 Gilead Sciences Business Overview
  64. 8.11.3 Gilead Sciences Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Gilead Sciences Therapeutic Radioligands Drug Product Portfolio
  66. 8.11.5 Gilead Sciences Recent Developments
  67. 8.12 Fusion Pharmaceuticals
  68. 8.12.1 Fusion Pharmaceuticals Company Information
  69. 8.12.2 Fusion Pharmaceuticals Business Overview
  70. 8.12.3 Fusion Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
  72. 8.12.5 Fusion Pharmaceuticals Recent Developments
  73. 8.13 Curium Pharmaceuticals
  74. 8.13.1 Curium Pharmaceuticals Company Information
  75. 8.13.2 Curium Pharmaceuticals Business Overview
  76. 8.13.3 Curium Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Curium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
  78. 8.13.5 Curium Pharmaceuticals Recent Developments
  79. 8.14 Curasight
  80. 8.14.1 Curasight Company Information
  81. 8.14.2 Curasight Business Overview
  82. 8.14.3 Curasight Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Curasight Therapeutic Radioligands Drug Product Portfolio
  84. 8.14.5 Curasight Recent Developments
  85. 8.15 Clarity Pharmaceuticals
  86. 8.15.1 Clarity Pharmaceuticals Company Information
  87. 8.15.2 Clarity Pharmaceuticals Business Overview
  88. 8.15.3 Clarity Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
  90. 8.15.5 Clarity Pharmaceuticals Recent Developments
  91. 8.16 China Isotope & Radiation
  92. 8.16.1 China Isotope & Radiation Company Information
  93. 8.16.2 China Isotope & Radiation Business Overview
  94. 8.16.3 China Isotope & Radiation Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 China Isotope & Radiation Therapeutic Radioligands Drug Product Portfolio
  96. 8.16.5 China Isotope & Radiation Recent Developments
  97. 8.17 Aurobindo Pharma
  98. 8.17.1 Aurobindo Pharma Company Information
  99. 8.17.2 Aurobindo Pharma Business Overview
  100. 8.17.3 Aurobindo Pharma Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Aurobindo Pharma Therapeutic Radioligands Drug Product Portfolio
  102. 8.17.5 Aurobindo Pharma Recent Developments
  103. 8.18 Actinium Pharmaceuticals
  104. 8.18.1 Actinium Pharmaceuticals Company Information
  105. 8.18.2 Actinium Pharmaceuticals Business Overview
  106. 8.18.3 Actinium Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
  108. 8.18.5 Actinium Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst